M
ost admissions for acute heart failure (AHF) occur in patients with chronic heart failure (HF). Despite significant improvements in prognosis for patients with stable HF, there has been essentially no progress in the treatment of AHF. After admission for decompensation, data showed high short-term mortality rates of 11% to 15% (1) . The prognosis does thus not differ between HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) (2) . Most of these admissions are for clinical congestion, not hypotension nor shock, regardless of ejection fraction (1, 2) . Hypervolemia is a significant risk marker in HF and is linked to impaired prognosis (3) . An important goal for decongestive treatment strategies is rapid attainment of stable euvolemic status. It is not clear to which extent values from euvolemic healthy persons are ideal for patients with HF (4). However, global and uncontrolled therapeutic interventions to reduce "increased" blood volume in decompensated HF can lead to excessive preload reduction, systemic hypoperfusion, and increased organ damage. Therefore, knowledge of a patient's actual volume status is important to monitor decongestive therapies.
In the clinical setting, it is often a challenge to assess true volume status and its distribution in the individual patient. Clinical markers such as elevated jugular venous distention, lower extremity edema, or S 3 remain inadequate. Parameters for hemoconcentration (e.g., increases in hemoglobin, hematocrit, or plasma albumin) are surrogates for changes in volume status, but they lack sensitivity and specificity (5,6). 
